Summary: A systematic review and meta-analysis led by University College London (UCL) found that GLP-1 receptor agonists—medications such as semaglutide, tirzepatide and liraglutide—produce more than just weight loss. The evidence indicates these drugs substantially reduce core symptoms of binge eating disorder (BED), including the frequency of binge episodes, loss-of-control eating and emotional eating, while also increasing measures of dietary restraint. The review highlights promising therapeutic potential but also emphasizes important limitations and the need for further high-quality trials.
Key Facts
- Behavioral benefit beyond weight loss: The review showed that GLP-1 receptor agonists are associated with measurable reductions in binge eating frequency, episodes of loss-of-control eating and emotional eating, suggesting effects that go beyond simple metabolic or gastric mechanisms.
- Dietary restraint requires caution: Treated participants tended to report higher cognitive or dietary restraint. Researchers caution that it is unclear whether this represents healthy self-regulation or a shift toward potentially problematic restrictive behaviours, and more research is needed to determine clinical meaning.
- Central nervous system action: In addition to slowing gastric emptying and modifying insulin secretion, GLP-1 agonists act on brain pathways involved in reward, dopamine signalling and impulse control, which may help dampen the intense cravings and compulsive urges that drive binge episodes.
- Inclusion of lived experience: The project incorporated a lived experience panel, whose members emphasized that medication alone is unlikely to produce lasting recovery. They recommended combining pharmacological treatments with psychological therapy, social support and efforts to reduce weight stigma.
- Methodological concerns: Most trials included in the review had a high risk of bias, were industry-funded and rarely enrolled people with a formal clinical diagnosis of BED. This limits certainty and points to an urgent need for large, independent trials focused on diagnosed populations.
- Access and equity gaps: Many people with binge eating symptoms cannot obtain these medications via public health systems and must seek private care at considerable cost. The authors hope stronger evidence will improve public access policy.
Source: UCL
Overview: Researchers at UCL conducted the largest synthesis to date examining how glucagon-like peptide-1 receptor agonists (GLP-1RAs) affect binge eating and related behaviours. Their systematic review and meta-analysis, published in eClinicalMedicine, pooled results from randomized controlled trials testing appetite-regulating medications including semaglutide, tirzepatide and liraglutide. The analysis focused on validated measures of binge eating, loss of control, emotional eating and dietary restraint.
Lead author Dr Ilaria Costantini (UCL Psychiatry) noted that binge eating disorder—defined by recurrent episodes of excessive eating experienced as a loss of control—affects millions worldwide and causes substantial impairment. With few approved pharmacological treatments for BED, novel therapeutic strategies are urgently needed. The UCL team found consistent signals that GLP-1RAs can help manage core symptoms in the short term.
The review combined data from 25 randomized controlled trials conducted across 12 countries, with 8,069 participants in total. Trials tested drugs that target the GLP-1 system and assessed outcomes including binge episode frequency, loss-of-control eating, emotional eating and measures of dietary restraint. Across pooled studies, the drugs produced reductions in binge-related behaviours and emotional eating while increasing cognitive restraint scores.
Izzy Emptage, the study’s first author and a PhD candidate at UCL Psychiatry, emphasized uncertainty around the rise in dietary restraint: “From the available evidence, we cannot determine whether higher restraint reflects adaptive self-control or an unhealthy restricted eating pattern. Future research should clarify whether these medications pose a risk of promoting pathological restriction, such as meal skipping.”
The authors stress that GLP-1RAs should be considered as one component in multimodal care for BED, not a standalone cure. The lived experience panel stressed that lasting recovery typically requires psychological therapies that address emotional and cognitive drivers of bingeing, social supports and broader efforts to reduce weight stigma in healthcare and society.
Limitations are important: most included trials had high or unclear risk of bias, many were industry-funded, and few specifically enrolled participants with a formal BED diagnosis. Heterogeneity across trials was substantial. The investigators call for adequately powered, independently funded randomized trials with longer follow-up and recruitment of people diagnosed with binge eating disorder to determine whether short-term improvements translate into durable clinical benefit.
Key questions answered
A: GLP-1 agonists influence appetite through peripheral effects such as delayed gastric emptying and altered insulin secretion, but they also act on central nervous system circuits that regulate reward, dopamine signalling and impulse control. By reducing the hyperactive reward responses and intense cravings that can drive compulsive bingeing, these drugs may lessen the urge to binge.
A: Dietary restraint is the conscious effort to limit food intake. Some degree of structure can be part of healthy recovery, but excessive restraint may indicate or lead to pathological restriction. The review found increased restraint scores among treated participants, and researchers warn that long-term effects and potential harms require careful monitoring.
A: Medication may reduce physiological cravings and blunt reward-driven urges, but it does not resolve underlying emotional, psychological or social triggers that drive binge eating. Psychological therapies and community support are essential to build coping skills and address the root causes of disordered eating so gains are maintained if medication is stopped.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by editorial staff.
About this psychopharmacology and eating disorder research news
Author: Chris Lane
Source: UCL
Contact: Chris Lane – UCL
Image: Image credited to Neuroscience News
Original Research: Open access. “The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis” by Tien-chen Lin et al. Published in eClinicalMedicine. DOI: 10.1016/j.eclinm.2026.104007
Abstract
The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis
Background
GLP-1RAs are widely prescribed for type 2 diabetes and weight management. Emerging evidence suggests they may also reduce binge eating behaviours and body dissatisfaction, but concerns remain about possible increases in dietary restraint. This review evaluated the available randomized trial evidence on GLP-1RAs for binge eating severity and related eating behaviours.
Methods
The authors performed a systematic review and meta-analysis of randomized controlled trials comparing GLP-1RAs with placebo or active comparators that reported validated measures of binge eating, disinhibited eating and loss-of-control eating. Databases searched covered trials from January 2005 to April 2026. Trials with participants who had severe physical comorbidities were excluded. Effect sizes were estimated using random-effects models.
Findings
Twenty-five RCTs (n = 8,069; roughly two-thirds female; majority White) met inclusion criteria. Compared with control conditions, GLP-1RA treatment was associated with moderate reductions in binge eating, loss-of-control eating and disinhibition, smaller reductions in emotional eating and an increase in cognitive or dietary restraint. Effects tended to be larger in trials that enrolled participants with binge eating disorder. Most studies raised concerns about bias and showed substantial heterogeneity.
Interpretation
GLP-1RAs appear to reduce binge eating–related behaviours and emotional eating while increasing dietary restraint; however, whether increased restraint is adaptive or harmful is unclear. Given study limitations, well-powered, independently funded trials with longer follow-up that recruit people diagnosed with binge eating disorder are needed to guide clinical practice.
Funding
Wellcome Trust and Medical Research Foundation.